

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

LISTING OF CLAIMS:

Claims 1-2. (Canceled)

Claim 3. (Currently amended) A method ~~according to claim 2~~ of delivering a peptide or protein to a cell comprising:

a) fusing a nucleic acid sequence encoding the peptide or protein to a modified human papillomavirus (HPV) L2 gene to create a fusion protein gene,;

b) expressing the fusion protein gene in a host cell to obtain fusion protein;

c) contacting the fusion protein with HPV L1 protein under conditions wherein the fusion protein and the L1 protein spontaneously combine to form a virus like particle (VLP);
and

d) delivering the VLP to the cell;

(i) wherein the modified HPV L2 gene encodes less than about 50% of wild type L2 protein and encodes domains from the amino and the carboxyl termini; and

(ii) wherein the HPV L2 gene is from an HPV strain selected from the group consisting of: HPV6a, HPV6b, HPV11, HPV16, HPV18, HPV31, HPV33, HPV35, HPV42, HPV43, HPV44, HPV45, HPV51, HPV52, and HPV56.

Claims 4-7. (Canceled)

Claim 8. (Original) A HPV virus-like particle (VLP) comprising HPV L1 protein and a fusion protein wherein the fusion protein comprises:

a first protein which is an HPV L2 protein which is less than about 50% of wild type; and

a second protein or peptide.

Claim 9. (Currently Amended) A VLP according to Claim 8 wherein the HPV L2 protein is from a HPV strain selected from the group consisting of: HPV6a, HPV6b, HPV11, HPV16, HPV18, HPV31, HPV33, HPV35, HPV42, HPV43, HPV44, HPV45, HPV51, HPV52, and HPV56.

Claim 10. (Original) A host cell comprising the VLP of Claim 8.

Claim 11. (Canceled)

Claim 12. (Original) A nucleic acid encoding a VLP according to Claim

9.